ClinicalTrials.gg
CompletedNCT04608149Updated Sep 14, 2026

Prospective, Multi-center, Single-arm, Observational Study. US FDA 522 Pediatric Post Market Surveillance Study.

An observational study in Acute Kidney Injury and Fluid Overload, sponsored by Mozarc Medical US LLC. Completed at 6 sites in United States. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Mozarc Medical US LLC · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
36
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Enrollment
99th of 131
36 · median 124
Started
2021
with 26 others
Observational
132 of 370
21 open now
Registered
238th of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 99th largest by enrollment of the 131 observational ones that give a count, is one of 27 that started in 2021, is one of 132 observational ones, and was the 238th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

The post market surveillance study will employ a prospective, multi-center, single-arm, observational design to capture data on children who undergo CRRT using the Carpediem™ system. Participating clinicians will manage subjects in accordance to their local standard of care practices and decisions on initiating, modifying or discontinuing CRRT are up to the local investigative team's prescription.

A minimum of 10 centers in the United States, that have been trained on the use of the Carpediem™ system, will be invited to participate in the study. After obtaining institutional review board approval and written informed consent from a parent or legally authorized representative (LAR), data from all subjects treated with the Carpediem™ system will be included in the study. A minimum of 35 subjects will be enrolled and sites may be asked to screen and enroll patients for the study for up to 36 months.

Status of subjects discharged from hospital will be collected at 30- and-90 days following hospital discharge by phone interviews in accordance to local standard of care practices, review of in-hospital records or in-clinic visit, as available.

Read the detailed description

The post market surveillance study is designed to capture data in the real-world clinical setting on the use of the Carpediem™ system and will evaluate the safety and performance in children requiring CRRT in the US. Data on survival and the effectiveness of the Carpediem™ system on renal function recovery will be evaluated. A comprehensive evaluation of subjects being treated with Carpediem™ will include, but is not limited to, acuity at hospital/ICU admission and prior to CRRT initiation, Carpediem™ treatment parameters, laboratory data, and requirement for mechanical ventilation and/or inotropic support. Subject status and requirement for renal replacement therapy post hospital discharge will be evaluated at 30- and 90-days.

03

Conditions studied

  • Acute Kidney Injury
  • Fluid Overload

Keywords

  • Carpediem(tm)
  • continuous renal replacment therapy
  • CRRT
  • acute kidney injury
  • pediatric
  • fluid overload
  • hemodialysis
  • hemofiltration
  • post market surveillance
  • registry
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who have acute kidney injury or fluid overload requiring hemodialysis or hemofiltration who weigh between 2.5 and 10 kilograms (5.5 to 22 pounds).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parent or LAR has signed information consent
  • Subject weighs between 2.5-10 kg (or 5.5-22 lbs)
  • Subject is receiving medical care in an intensive care unit
  • Parental or LAR consent to receive full supportive care through aggressive management utilizing all available therapies for a minimum of 96 hours
  • Subject has a clinical diagnosis of acute kidney injury per Kidney Disease Improving Global Outcomes (KDIGO) criteria or fluid overload requiring CRRT

Exclusion criteria

Exclusion Criteria:

  • Subject is not expected to survive 72 hours due to an irreversible medical condition, in the opinion of the investigator
  • Subject has irreversible brain damage, in the opinion of the investigator
  • Subject is intolerant to anticoagulation, as documented in the medical record
  • Subject has a Do Not Attempt Resuscitate (DNAR), Allow Natural Death (AND), withdrawal of care or similar order, or anticipated change in status, in the opinion of the investigator, within the next 7 days
  • Subject has pre-existing end-stage renal disease or pre-existing, advanced chronic kidney disease, defined as an estimated (eGRF) \< 30 ml/min/1.73m2
  • Subject is currently or has chronically been treated with a circulatory support device (i.e., left ventricular assist device (LVAD)) other than ECMO
  • Subject has had prior CRRT treatments using the Carpediem™ system
  • Subject is enrolled in clinical trials or being treated with other therapeutic devices or products for acute kidney injury or fluid overload
  • Subject has any other medical condition that may confound the study objectives, in the opinion of the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
36 participants (actual)
Target follow-up
120 Days
Patient registry
Yes

Groups and cohorts

  • Subjects treated with Carpediem system

    All patients who receive CRRT with the Carpediem™ system, as prescribed by the investigator, will be offered participation in the post market surveillance study after obtaining parental consent.

    Device: Carpediem System

Interventions

  • DeviceCarpediem System

    Continuous renal replacement therapy

06

What researchers measure

Primary outcomes

  1. Survival at CRRT Discontinuation

    Evaluation subject survival at CRRT discontinuation

    Time frame: from the start of CRRT to the date of death or CRRT discontinuation, assessed up to 100 weeks

  2. Survival at intensive care unit (ICU) discharge

    Evaluation subject survival at ICU discharge

    Time frame: from the start of CRRT to the date of death or ICU dhscharge, assessed up to 100 weeks

Secondary outcomes

  1. Survival through 90 days post hospital discharge

    Quantify survival at hospital discharge, and 30- and 90-days post hospital discharge

    Time frame: hospital discharge through 90 days post discharge

  2. Hospital and ICU length of stay

    Evaluation hospital and ICU length of stay

    Time frame: through discharge, assessed up to 100 weeks

  3. Renal function recovery at discharge and 30- and 90- days post hospital discharge

    Assess renal function recovery at hospital discharge and 30- and 90- days post hospital discharge

    Time frame: Hospital discharge through 90 days post discharge

  4. Overall survival

    Characterize overall survival based on variables including, but not limited to; demographic data, laboratory values, patient acuity prior to CRRT initiation and CRRT treatment parameters

    Time frame: through study completion, an average of 3 years

  5. Time to CRRT discontinuation

    Assess time to CRRT discontinuation

    Time frame: from the start of CRRT to the date of death or CRRT discontinuation, assessed up to 100 weeks

  6. Carpediem system-related adverse events

    Quantify the rate of Carpediem system-related adverse events

    Time frame: through study completion, an average of 3 years

07

Study locations

6 sites
  • University of Iowa Healthcare
    Iowa City, Iowa 52252, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Golisano Children's Hospital
    Rochester, New York 14642, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Seattle Children's
    Seattle, Washington 98103, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Apr 2026, 63 months.

Of 365 observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 63 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2020
First posted
Oct 29, 2020
StartActual
Jan 20, 2021
Primary completionActual
Apr 30, 2026
CompletionActual
Apr 30, 2026
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04608149
Lead sponsor
Mozarc Medical US LLC
Responsible party
Sponsor
First posted
Oct 29, 2020
Start date
Jan 20, 2021
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026
Last update
Sep 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion